16 / 64
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 6, November/December 2020
296
AFRICA
Victoria Foundation, the Lennart Hanssons Memorial Fund, Knut and
Alice Wallenberg Foundation, and the Marianne and Marcus Wallenberg
Foundation. Dr Nilsson was funded by the Research Council of Sweden
(K2008-65X-20752-01-3 and K2011-65X-20752-04-6), E Lundström
Foundation and ALF from Region Skåne. The funders had no role in the
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
This study was previously presented as an abstract at the Heart Failure
Congress in Vienna on 27 May 2018.
References
1.
Levin ER, Gardner DG, Samson WK. Natriuretic peptides.
N Engl J
Med
1998;
339
(5): 321–328.
2.
Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular
biology, and clinical relevance of natriuretic peptides.
J Cardiol
2011;
57
(2): 131–140.
3.
Kim HN, Januzzi JL, Jr. Natriuretic peptide testing in heart failure.
Circulation
2011;
123
(18): 2015–2019.
4.
De Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M, Khoshbaten
A. The physiological and pathophysiological modulation of the endo-
crine function of the heart.
Can J Physiol Pharmacol
2001;
79
(8):
705–714.
5.
Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of
the measurement of cardiac natriuretic peptides: a review.
Clin Chem
2004;
50
(1): 33–50.
6.
Jujic A, Nilsson PM, Engstrom G, Hedblad B, Melander O, Magnusson
M. Atrial natriuretic peptide and type 2 diabetes development –
biomarker and genotype association study.
PLoS One
2014;
9
(2):
e89201.
7.
Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J,
et al
. Low plasma level of atrial natriuretic peptide predicts develop-
ment of diabetes: the prospective Malmo Diet and Cancer study.
J Clin
Endocrinol Metab
2012;
97
(2): 638–645.
8.
Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS.
Association of plasma natriuretic peptide levels with metabolic risk
factors in ambulatory individuals.
Circulation
2007;
115
(11): 1345–1353.
9.
Jujic A, Nilsson PM, Persson M, Holst JJ, Torekov SS, Lyssenko V,
et
al
. Atrial natriuretic peptide in the high normal range is associated with
lower prevalence of insulin resistance.
J Clin Endocrinol Metab
2016;
101
(4): 1372–1380.
10. Wang TJ, Larson MG, Levy D, Benjamin EJ, Corey D, Leip EP,
et al.
Heritability and genetic linkage of plasma natriuretic peptide levels.
Circulation
2003;
108
(1): 13–16.
11. Gupta DK, Claggett B, Wells Q, Cheng S, Li M, Maruthur N,
et al.
Racial differences in circulating natriuretic peptide levels: the atheroscle-
rosis risk in communities study.
J Am Heart Assoc
2015;
4
(5): e001831.
12. DeFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL.
Dynamic cardiovascular risk assessment in elderly people. The role of
repeated N-terminal pro-B-type natriuretic peptide testing.
J Am Coll
Cardiol
2010;
55
(5): 441–450.
13. Choi EY, Bahrami H, Wu CO, Greenland P, Cushman M, Daniels LB,
et al
. N-terminal pro-B-type natriuretic peptide, left ventricular mass,
and incident heart failure: multi-ethnic study of atherosclerosis.
Circ
Heart Fail
2012;
5
(6): 727–734.
14. Gupta DK, de Lemos JA, Ayers CR, Berry JD, Wang TJ. Racial differ-
ences in natriuretic peptide levels: the Dallas Heart Study.
J Am Coll
Cardiol Heart Fail
2015;
3
(7): 513–519.
15. Van Vuren EJ, Malan L, von Kanel R, Cockeran M, Malan NT.
Hyperpulsatile pressure, systemic inflammation and cardiac stress are
associated with cardiac wall remodeling in an African male cohort: the
SABPA study.
Hypertens Res
2016;
39
(9): 648–653.
16. Malan L, Hamer M, Frasure-Smith N, Steyn HS, Malan NT. Cohort
Profile: Sympathetic activity and Ambulatory Blood Pressure in
Africans (SABPA) prospective cohort study.
Int J Epidemiol
2015;
44
(6):
1814–1822.
17. Norton K, Olds T (eds).
Anthropometrica: A textbook of body measure-
ments for sports and health courses.
1996.
18. Botha J, de Ridder JH, Potgieter JC, Steyn HS, Malan L. Structural
vascular disease in Africans: performance of ethnic-specific waist
circumference cut points using logistic regression and neural network
analyses: The SABPA study.
Exp Clin Endocrinol Diabetes
2013;
121
(9):
515–520.
19. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato
KA,
et al.
Harmonizing the metabolic syndrome: a joint interim
statement of the International Diabetes Federation Task Force on
Epidemiology and Prevention; National Heart, Lung, and Blood
Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association for
the Study of Obesity.
Circulation
2009;
120
(16): 1640–1645.
20. Collins S. A heart-adipose tissue connection in the regulation of energy
metabolism.
Nat Rev Endocrinol
2014;
10
(3): 157–163.
21. Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke
G,
et al
. Atrial natriuretic peptide induces postprandial lipid oxidation
in humans.
Diabetes
2008;
57
(12): 3199–3204.
22. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V,
et
al
. Atrial natriuretic peptide inhibits the production of adipokines and
cytokines linked to inflammation and insulin resistance in human subcu-
taneous adipose tissue.
Diabetologia
2007;
50
(5): 1038–1047.
23. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C,
McCabe EL,
et al
. Cardiac natriuretic peptides, obesity, and insu-
lin resistance: evidence from two community-based studies.
J Clin
Endocrinol Metab
2011;
96
(10): 3242–3249.
24. Fliser D, Buchholz K, Haller H, and for the EUropean Trial on
Olmesartan and Pravastatin in Inflammation and Atherosclerosis
(EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II
subtype 1 receptor blockade in hypertensive patients with microinflam-
mation.
Circulation
2004;
110
(9): 1103–1107.
25. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A,
et al
.
Thirty-one novel biomarkers as predictors for clinically incident diabe-
tes.
PLoS One
2010;
5
(4): e10100.
26. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW,
et
al
. Plasma natriuretic peptides for community screening for left ventricu-
lar hypertrophy and systolic dysfunction: the Framingham heart study.
J
Am Med Assoc
2002;
288
(10): 1252–1259.
27. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in
cardiac disease and other comorbid conditions.
Heart Fail Rev
2007;
12
(1): 23–36.
28. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM,
Engelgau MM,
et al
. Prevalence of diabetes and impaired fasting
glucose in adults in the U.S. population: National Health And Nutrition
Examination Survey 1999–2002.
Diabetes Care
2006;
29
(6): 1263–1268.
29. Haffner SM, D’Agostino R, Saad MF, Rewers M, Mykkanen L, Selby
J,
et al
. Increased insulin resistance and insulin secretion in nondiabetic
African-Americans and Hispanics compared with non-Hispanic whites.
The Insulin Resistance Atherosclerosis Study.
Diabetes
1996;
45
(6):
742–748.
30. Sanchez OA, Duprez DA, Bahrami H, Daniels LB, Folsom AR,
Lima JA,
et al.
The associations between metabolic variables and
NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study